

7th November, 2019

BSE Limited
P J Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 532300

National Stock Exchange of India Limited
Exchange Plaza
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE Symbol: WOCKPHARMA

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with Schedule III of Listing Regulations, we wish to enclose herewith:

- I. Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September, 2019, as approved by the Board of Directors at its meeting held today; and
- II. Limited Review Report issued by BSR & Co. LLP., Statutory Auditors of the Company.

Also please find enclosed herewith copy of the Press Release proposed to be issued in respect of the said Financial Results; and extract of Unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2019, being published in the Newspapers.

The Board Meeting commenced at 2.15 p.m. and concluded at 3.30 p.m.

Kindly take the same on your record.

Thanking you,

For **Wockhardt Limited**

Narendra Singh
Company Secretary

Encl.: As above



WOCKHARDT LIMITED
Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
CIN:L24230MH1999PLC120720
Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com

(Rs. In Crore except per share data)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2019

PARTICULARS	3 MONTHS ENDED 30/09/2019	3 MONTHS ENDED 30/06/2019	3 MONTHS ENDED 30/09/2018	6 MONTHS ENDED 30/09/2019	6 MONTHS ENDED 30/09/2018	YEAR ENDED 31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(Refer notes below)						
1 Income						
(a) Revenue from operations	424.28	352.21	634.59	776.49	1,173.95	2,149.95
(b) Other income	2.01	8.61	8.38	10.62	16.71	31.00
Total income	426.29	360.82	642.97	787.11	1,190.66	2,180.95
2 Expenses						
(a) Cost of materials consumed	58.58	82.47	129.49	141.05	243.32	464.73
(b) Purchase of stock-in-trade	41.88	38.93	110.43	80.81	239.26	402.48
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	16.44	(3.57)	32.06	12.87	11.41	5.03
(d) Employee benefits expense	112.34	131.67	134.79	244.01	271.47	482.20
(e) Finance costs	54.27	56.26	43.41	110.53	81.33	170.63
(f) Depreciation and amortisation expense	42.00	44.40	28.64	86.40	56.12	121.91
(g) Exchange fluctuation loss / (gain), net	(11.75)	3.37	(23.16)	(8.38)	(39.62)	(3.80)
(h) Other expenses	111.05	140.47	178.73	251.52	335.67	713.20
Total expenses	424.81	494.00	634.39	918.81	1,198.96	2,356.38
3 Profit / (Loss) before tax (1-2)	1.48	(133.18)	8.58	(131.70)	(8.30)	(175.43)
4 Tax expense:						
Current tax	-	-	-	-	-	-
Deferred tax (credit)/charge	1.41	(50.25)	3.48	(48.84)	1.71	(93.54)
5 Net Profit / (Loss) after tax (3 ± 4)	0.07	(82.93)	5.10	(82.86)	(10.01)	(81.89)
6 Other Comprehensive Income						
a) Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset)	(0.47)	(0.46)	(0.18)	(0.93)	0.17	(1.86)
b) Income tax relating to items that will not be reclassified to Profit or Loss - (charge)/credit	0.19	0.18	0.04	0.37	(0.03)	0.66
c) Other Comprehensive Income (net of tax) (6a ± 6b)	(0.28)	(0.28)	(0.14)	(0.56)	0.14	(1.20)
7 Total Comprehensive Income (5 ± 6c)	(0.21)	(83.21)	4.96	(83.42)	(9.87)	(83.09)
8 Paid-up equity share capital (face value of Rs. 5/- each)	55.37	55.35	55.33	55.37	55.33	55.34
9 Other Equity excluding Revaluation Reserves as per balance sheet						1,171.29
10 Earnings per share (face value of Rs. 5/- each) (*not annualised)						
(a) Basic (Rs.)	0.01*	(7.49)*	0.46*	(7.49)*	(0.91)*	(7.40)
(b) Diluted (Rs.)	0.01*	(7.49)*	0.45*	(7.49)*	(0.91)*	(7.40)



Notes To Standalone Results :-


- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 07, 2019. The results have been subjected to limited review by the Statutory Auditors of the Company. The Statement of Cash Flows for the corresponding period from April 01, 2018 to September 30, 2018, as reported in these unaudited standalone financial results have been approved by the Board of Directors, but have not been subjected to review.
- 2) During the quarter, the Company has allotted 30,000 Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options.
- 3) The Company has adopted Ind AS 116 – Leases beginning April 01, 2019 using the modified retrospective approach. The standard has been applied to all the lease contracts existing as on April 01, 2019. Accordingly, the Company has not restated comparative information and recognised a lease liability at present value of the lease payments discounted at the relevant incremental borrowing rate. The right-of-use asset has been measured at the same value as that of the lease liability subject to the adjustments for prepayments and accruals. For leases classified as finance lease, the carrying value of the lease asset and lease liability as at April 01, 2019, has been carried forward without change under the new standard.

Consequent to the new standard, the Company has reported Right-of-Use assets amounting Rs. 644.25 crore (including reclassification of Lease hold land) and Lease liability amounting to Rs. 519.75 crore as on April 01, 2019.
- 4) The Company is exclusively into Pharmaceutical business Segment.
- 5) Previous period / year figures have been recast / re-grouped to conform to the current period's presentation.

Mumbai

Date : November 07, 2019

FOR WOCKHARDT LIMITED



H F KHORAKIWALA

CHAIRMAN

DIN: 00045608




STATEMENT OF STANDALONE ASSETS AND LIABILITIES

(Rs. in Crore)

	PARTICULARS	As at Period End 30/09/2019 Unaudited	As at Year End 31/03/2019 Audited
A)	ASSETS		
	1 Non- Current assets		
	(a) Property, Plant and Equipment	1,448.52	1,589.26
	(b) Right of use assets	618.22	-
	(c) Capital work-in-progress	374.55	380.90
	(d) Intangible assets	23.07	25.06
	(e) Financial assets		
	(i) Investments in subsidiaries	296.82	296.82
	(ii) Other Investments	0.45	0.45
	(iii) Other non- current Financial assets	85.84	80.88
	(f) Non-current tax assets (Net)	99.77	99.45
	(g) Deferred tax assets (Net)	187.76	138.55
	(h) Other non-current assets	74.42	96.52
	Sub-total- Non-current assets	3,209.42	2,707.89
	2 Current assets		
	(a) Inventories	347.12	370.04
	(b) Financial assets		
	(i) Trade receivables	1,013.24	1,005.01
	(ii) Cash and cash equivalents	82.02	177.07
	(iii) Bank balance (other than (ii) above)	50.99	49.14
	(iv) Other current Financial assets	16.89	19.72
	(c) Other current assets	162.25	208.96
	Sub-total - Current assets	1,672.51	1,829.94
	TOTAL ASSETS	4,881.93	4,537.83
B)	EQUITY AND LIABILITIES		
	1 Equity		
	(a) Equity share capital	55.37	55.34
	(b) Other Equity	1,088.78	1,171.29
	Sub-total- Equity	1,144.15	1,226.63
	2 Liabilities		
	I. Non- Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	815.96	941.93
	(ii) Lease Liabilities	481.48	-
	(b) Provisions	48.37	44.26
	(c) Other non-current liabilities	490.54	497.27
	Sub-total- Non-current liabilities	1,836.35	1,483.46
	II. Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	696.30	561.71
	(ii) Trade payables		
	a. Due to Micro enterprises and Small enterprises	59.15	78.83
	b. Due to Others	541.70	539.92
	(iii) Lease Liabilities	26.61	-
	(iv) Other financial liabilities	466.41	535.56
	(b) Other current liabilities	72.21	75.50
	(c) Provisions	38.24	35.41
	(d) Current tax liabilities (Net)	0.81	0.81
	Sub-total- Current liabilities	1,901.43	1,827.74
	TOTAL EQUITY AND LIABILITIES	4,881.93	4,537.83

FOR WOCKHARDT LIMITED



H F KHORAKIWALA
CHAIRMAN
DIN: 00045608



Mumbai
Date: November 07, 2019



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalhana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

UNAUDITED CASH FLOW STATEMENT FOR SIX MONTHS ENDED SEPTEMBER 30, 2019


(Rs. in Crore)

PARTICULARS	6 MONTHS ENDED 30/09/2019	6 MONTHS ENDED 30/09/2018
	Unaudited	Unaudited
(Refer notes below)		
A CASH FLOWS FROM/(USED IN) OPERATING ACTIVITIES:		
Net Loss before taxation	(131.70)	(8.30)
Adjustments for:		
Depreciation and amortisation expense	86.40	56.12
Liabilities no more payable	(1.38)	(0.48)
Allowance for credit loss	8.25	(5.36)
Provision for doubtful advances	3.48	(3.25)
Bad Debts	1.12	7.50
Unrealised Exchange fluctuation loss/(gain), net	19.81	(1.80)
Loss on assets sold/write off of fixed assets (net)	0.16	0.08
Finance costs	110.53	81.33
Interest income	(2.75)	(6.94)
Fair valuation impact on deposits	(1.39)	1.61
Guarantee fees	(5.38)	(7.24)
Share based payments to Employees	1.35	2.55
Operating profit before Working Capital changes	88.50	115.82
Movement in working capital:		
Decrease/(Increase) in Inventories	22.92	(3.57)
(Increase) in Trade receivables	(37.68)	(202.47)
Decrease in Loans and Advances and other assets	41.32	21.49
Increase in Liabilities and provisions	27.89	2.93
(Decrease) in Trade payables	(12.25)	5.30
Cash from/(used in) Operations	130.70	(60.50)
Income taxes paid	(0.32)	(0.44)
Net cash from/(used in) Operating Activities (A)	130.38	(60.94)
B CASH FLOWS FROM/(USED IN) INVESTING ACTIVITIES:		
Purchase of Property, Plant and Equipment, Capital work-in progress and Intangible assets	(16.46)	(17.22)
Proceeds relating to Property, Plant and Equipment	0.06	0.05
Margin money under lien and Bank balances (other than cash and cash equivalents)	(1.86)	130.76
Interest received	4.29	5.42
Net cash (used in)/from Investing Activities (B)	(13.97)	119.01
C CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES:		
Proceeds from Issuance of Equity share capital	0.03	0.01
Repayment of long-term borrowings	(139.41)	(116.03)
Repayment of Lease liabilities	(35.52)	-
Short-term borrowings (net)	36.10	142.34
Finance costs paid	(73.00)	(57.67)
Equity Dividend	0.34	-
Net cash used in Financing Activities (C)	(211.46)	(31.35)
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS (A+B+C)	(95.05)	26.72
CASH AND CASH EQUIVALENTS, at beginning of period	177.07	67.83
CASH AND CASH EQUIVALENTS, at end of period	82.02	94.55
Component of cash and cash equivalents:		
Cash	-	0.00
Balance with banks:		
-in current account	72.00	79.16
Deposits with maturity of less than 3 months	10.02	15.30
	82.02	94.55

Notes:

1. All figures in bracket are outflow.
2. Income taxes paid are treated as arising from operating activities and are not bifurcated between investing and financing activities.

FOR WOCKHARDT LIMITED


H F KHORAKIWALA
 CHAIRMAN
 DIN: 00045608



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CIN: L24230MH1999PLC120720

Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

(Rs. in Crore except per share data)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2019

PARTICULARS	3 MONTHS ENDED 30/09/2019	3 MONTHS ENDED 30/06/2019	3 MONTHS ENDED 30/09/2018	6 MONTHS ENDED 30/09/2019	6 MONTHS ENDED 30/09/2018	YEAR ENDED 31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(Refer Notes Below)						
1 Income						
(a) Revenue from operations	802.18	863.11	1,125.68	1,665.29	2,133.39	4,158.38
(b) Other income	(0.20)	8.08	6.09	7.88	13.52	21.02
Total Income	801.98	871.19	1,131.77	1,673.17	2,146.91	4,179.40
2 Expenses						
(a) Cost of materials consumed	147.80	169.79	247.68	317.59	459.12	854.18
(b) Purchase of stock-in-trade	148.88	154.63	235.02	303.51	508.51	919.09
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	24.88	28.32	6.09	53.20	(50.44)	41.36
(d) Employee benefits expense	216.46	238.40	255.55	454.86	499.28	936.90
(e) Finance costs	64.64	70.89	65.10	135.53	137.75	264.89
(f) Depreciation and amortisation expense	53.36	54.96	40.20	108.32	79.37	166.04
(g) Exchange fluctuation loss / (gain), net	(4.44)	15.67	(15.33)	11.23	8.96	25.36
(h) Other expenses	220.95	216.39	329.25	437.34	636.09	1,271.90
Total expenses	872.53	949.05	1,163.56	1,821.58	2,278.64	4,479.72
3 Profit / (Loss) before tax (1-2)	(70.55)	(77.86)	(31.79)	(148.41)	(131.73)	(300.32)
4 Tax expense:						
Current tax	(1.15)	6.87	3.96	5.72	4.33	9.17
Deferred tax (credit) / charge	24.84	(47.85)	(4.91)	(23.01)	(10.16)	(92.83)
5 Profit / (Loss) after tax (3±4)	(94.24)	(36.88)	(30.84)	(131.12)	(125.90)	(216.66)
Attributable to :						
Equity shareholders of the Company	(82.17)	(44.98)	(22.77)	(127.15)	(108.95)	(194.53)
Non - Controlling Interest	(12.07)	8.10	(8.07)	(3.97)	(16.95)	(22.13)
6 Other Comprehensive Income						
(a) Items that will not be reclassified to Profit or Loss - (charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset)	(13.89)	5.62	11.53	(8.27)	19.98	(10.57)
(b) Income tax relating to items that will not be reclassified to Profit or Loss - (charge) / credit	2.48	(0.86)	(1.91)	1.62	(3.40)	0.26
(c) Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations)	(1.76)	1.39	97.01	(0.37)	118.21	19.31
(d) Other Comprehensive Income (net of tax) (6a ± 6b ± 6c)	(13.17)	6.15	106.63	(7.02)	134.79	9.00
7 Total Comprehensive Income (5 ± 6 (d))	(107.41)	(30.73)	75.79	(138.14)	8.89	(207.66)
Attributable to :						
Equity shareholders of the Company	(93.52)	(39.74)	68.77	(133.26)	6.79	(191.76)
Non - Controlling Interest	(13.89)	9.01	7.02	(4.88)	2.10	(15.90)
8 Paid-up equity share capital (face value of Rs. 5/- each)	55.37	55.35	55.33	55.37	55.33	55.34
9 Other Equity excluding Revaluation Reserves as per Balance Sheet						2,619.46
10 Earnings per share (face value of Rs. 5/- each) (*not annualised)						
(a) Basic (Rs.)	(7.42)*	(4.06)*	(2.06)*	(11.49)*	(9.85)*	(17.58)
(b) Diluted (Rs.)	(7.42)*	(4.06)*	(2.06)*	(11.49)*	(9.85)*	(17.58)



Notes To Consolidated Results:-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 07, 2019. The results have been subjected to limited review by the Statutory Auditors of the Company. The Statement of Cash Flows for the corresponding period from April 01, 2018 to September 30, 2018, as reported in these unaudited consolidated financial results have been approved by the Board of Directors, but have not been subjected to review.
- 2) The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
- 3) During the quarter, the Company has allotted 30,000 equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options.
- 4) **Key Financials on Standalone basis:**

(Rs. In Crore)

PARTICULARS	3 MONTHS ENDED 30/09/2019	3 MONTHS ENDED 30/06/2019	3 MONTHS ENDED 30/09/2018	6 MONTHS ENDED 30/09/2019	6 MONTHS ENDED 30/09/2018	YEAR ENDED 31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	424.28	352.21	634.59	776.49	1,173.95	2,149.95
Profit / (Loss) Before Tax	1.48	(133.18)	8.58	(131.70)	(8.30)	(175.43)
Profit / (Loss) After Tax	0.07	(82.93)	5.10	(82.86)	(10.01)	(81.89)

Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

- 5) The Group has adopted Ind AS 116 – Leases beginning April 01, 2019 using the modified retrospective approach. The standard has been applied to all the lease contracts existing as on April 01, 2019. Accordingly, the Group has not restated comparative information and recognised a lease liability at present value of the lease payments discounted at the relevant incremental borrowing rate. The right-of-use asset has been measured at the same value as that of the lease liability subject to the adjustments for prepayments and accruals. For leases classified as finance lease, the carrying value of the lease asset and lease liability as at April 01, 2019, has been carried forward without change under the new standard. Consequent to the new standard, the Group has reported Right-of-Use assets amounting Rs. 683.24 crore (including reclassification of Lease hold land) and Lease liability amounting to Rs. 397.93 crore as on April 01, 2019.
- 6) The Group is exclusively into Pharmaceutical business Segment.
- 7) For List of Subsidiaries as on September 30, 2019 please refer Annexure.
- 8) Previous period / year figures have been recast / re-grouped to conform to the current period's presentation.

FOR WOCKHARDT LIMITED



H.F. KHORAKIWALA
CHAIRMAN
DIN: 00046608

Mumbai
Date : November 07, 2019



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051


STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

(Rs. In Crore)

PARTICULARS	As at Period End	As at Year End
	30/09/2019	31/03/2019
	Unaudited	Audited
A) ASSETS		
1 Non- Current assets		
(a) Property, Plant and Equipment	1,802.99	2,124.50
(b) Right of use assets	652.56	-
(c) Capital work-in-progress	923.89	899.72
(d) Goodwill	817.52	820.56
(e) Other Intangible assets	110.41	112.87
(f) Intangible assets under development	642.62	545.76
(g) Financial assets		
(i) Non-current investments	0.45	0.45
(ii) Other non- current Financial assets	36.28	38.58
(h) Non-current tax assets (Net)	114.88	113.08
(i) Deferred tax assets (Net)	304.72	273.27
(j) Other non-current assets	74.32	100.87
Sub-total - Non-current assets	5,480.64	5,029.66
2 Current assets		
(a) Inventories	730.84	819.36
(b) Financial assets		
(i) Investments	-	-
(ii) Trade receivables	1,095.92	1,260.69
(iii) Cash and cash equivalents	196.53	397.34
(iv) Bank balance [other than (iii) above]	53.16	51.31
(v) Other current Financial assets	17.15	20.18
(c) Other current assets	209.86	252.56
Sub-total - Current assets	2,303.46	2,801.44
TOTAL ASSETS	7,784.10	7,831.10
B) EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	55.37	55.34
(b) Other Equity	2,482.10	2,619.46
Equity attributable to the share holders of the Company	2,537.47	2,674.80
(c) Non - Controlling Interest	326.71	329.83
Sub-total- Equity	2,864.18	3,004.63
2 Liabilities		
I. Non- Current liabilities		
(a) Financial liabilities		
(i) Borrowings	1,514.38	1,891.47
(ii) Lease Liabilities	350.70	-
(b) Provisions	61.49	53.48
(c) Deferred tax liabilities (Net)	39.73	31.07
Sub-total- Non-current liabilities	1,966.30	1,976.02
II. Current liabilities		
(a) Financial liabilities		
(i) Borrowings	696.30	561.71
(ii) Trade payables		
- Due to Micro enterprises and Small enterprises	59.15	78.84
- Due to Others	816.02	761.40
(iii) Lease Liabilities	32.96	-
(iv) Other financial liabilities	1,210.56	1,330.85
(b) Other current liabilities	75.01	69.53
(c) Provisions	60.65	41.93
(d) Current tax liabilities (Net)	2.97	6.19
Sub-total- Current liabilities	2,953.62	2,850.45
TOTAL EQUITY AND LIABILITIES	7,784.10	7,831.10

FOR WOCKHARDT LIMITED

[Signature]
H F KHORAKIWALA
CHAIRMAN
DIN: 00045608



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CONSOLIDATED UNAUDITED CASH FLOW STATEMENT FOR SIX MONTHS ENDED SEPTEMBER 30, 2019

		(Rs in crore)	
PARTICULARS		6 MONTHS ENDED 30/09/2019	6 MONTHS ENDED 30/09/2018
(Refer notes below)		Unaudited	Unaudited
A	CASH FLOWS FROM / (USED IN) OPERATING ACTIVITIES:		
	Net Loss before Tax	(148.41)	(131.73)
	Adjustments for :		
	Depreciation and amortization expense	108.32	79.37
	Liabilities no more payable	(1.39)	(0.48)
	Provision for doubtful advances	12.79	(8.11)
	Bad debts	1.12	(0.84)
	Unrealised exchange fluctuation loss / (gain), net	19.81	8.96
	Loss on assets sold / write off of fixed assets (net)	1.40	0.24
	Loss / (profit) on sale of investments	-	1.62
	Finance costs	135.53	137.75
	Interest income	(2.69)	(11.74)
	Fair valuation impact on certain financial instruments	1.13	1.10
	Share based payments to Employees	1.35	2.55
	MTM loss / (gain) on current investment	-	0.48
	Income from investment	-	(0.23)
	Operating profit before Working Capital changes	128.96	78.94
	Movement In working capital		
	(Increase) / Decrease in inventories	88.52	(72.30)
	(Increase) / Decrease in trade receivables	142.14	(318.39)
	(Increase) / Decrease in loans and advances and other assets	52.31	(30.46)
	Increase / (decrease) in liabilities and provisions	(23.92)	41.86
	Increase / (decrease) in trade payables	35.13	74.94
	Adjustment for translation difference in working capital	(7.79)	97.11
	Cash from/ (used in) operations	415.35	(128.30)
	Income taxes paid	(1.25)	(5.40)
	Net cash from / (used in) Operating Activities (A)	414.10	(133.70)
B	CASH FLOWS FROM / (USED IN) INVESTING ACTIVITIES:		
	Purchase of Property, Plant and Equipment, capital work in progress, other intangible assets and intangibles assets under development	(89.62)	(111.91)
	Proceeds from sale of Property, Plant and Equipment	0.06	0.24
	Sale / (purchase) of investments	-	185.72
	Margin money (under lien) and Bank balances (other than cash and cash equivalents)	(2.02)	130.79
	Income from Investment	-	0.23
	Interest received	4.94	10.36
	Net cash from / (used in) Investing Activities (B)	(86.64)	215.43
C	CASH FLOWS FROM / (USED IN) FINANCING ACTIVITIES		
	Proceeds from issuance of Equity share capital	0.03	0.01
	Repayment of long-term borrowings	(408.00)	(402.35)
	Repayment of Lease liabilities	(31.82)	-
	Short-term borrowings (net)	36.10	142.34
	Finance cost paid	(123.88)	(127.68)
	Equity dividend	0.34	-
	Net cash from / (used in) Financing Activities (C)	(527.23)	(387.68)
	NET DECREASE IN CASH AND CASH EQUIVALENTS (A+B+C)	(199.77)	(305.95)
	CASH AND CASH EQUIVALENTS, at beginning of period	397.34	897.24
	Unrealised gain / (loss) on foreign currency cash and cash equivalents	(1.04)	(3.37)
	CASH AND CASH EQUIVALENTS, at end of period	196.53	587.92
	Components of cash and cash equivalents:		
	Cash	0.08	0.09
	Balance with banks:		
	- In current accounts	186.43	391.04
	- deposit with maturity of less than 3 months	10.02	196.79
		196.53	587.92

Notes:

1. All figures in bracket are outflow.
2. Income taxes paid are treated as arising from operating activities and are not bifurcated between investing and financing activities.



FOR WOCKHARDT LIMITED

[Signature]
H F KHORAKIWALA
CHAIRMAN
DIN: 00045608

Mumbai
Date : November 07, 2019



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Annexure to Note 7 of Consolidated Unaudited Results for the Quarter and Six Months ended September 30, 2019

List of Subsidiaries as on September 30, 2019

- 1 Wockhardt UK Holdings Limited
- 2 CP Pharmaceuticals Limited
- 3 CP Pharma (Schweiz) AG
- 4 Wallis Group Limited
- 5 The Wallis Laboratory Limited
- 6 Wockhardt Farmaceutica Do Brasil Ltda
- 7 Wallis Licensing Limited
- 8 Wockhardt Infrastructure Development Limited
- 9 Z & Z Services GmbH
- 10 Wockhardt Europe Limited
- 11 Wockhardt Nigeria Limited
- 12 Wockhardt USA LLC
- 13 Wockhardt UK Limited
- 14 Wockpharma Ireland Limited
- 15 Pinewood Laboratories Limited
- 16 Pinewood Healthcare Limited
- 17 Laboratoires Negma S.A.S.
- 18 Wockhardt France (Holdings) S.A.S.
- 19 Wockhardt Holding Corp.
- 20 Morton Grove Pharmaceuticals Inc.
- 21 MGP Inc.
- 22 Laboratoires Pharma 2000 S.A.S.
- 23 Niverpharma S.A.S.
- 24 Negma Beneulex S.A.
- 25 Phytex S.A.S.
- 26 Wockhardt Farmaceutica SA DE CV
- 27 Wockhardt Services SA DE CV
- 28 Wockhardt Bio AG
- 29 Wockhardt Bio (R) LLC
- 30 Wockhardt Bio Pty Limited
- 31 Wockhardt Bio Limited
- 32 Wockhardt Medicines Limited



BSR & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on Unaudited Quarterly and Year to Date Standalone Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Wockhardt Limited ("the Company") for the quarter ended and year to date results for the period from 1 April 2019 to 30 September 2019 ("the Statement"). Attention is drawn to the fact that the figures for net cash inflows for the corresponding period from 1 April 2018 to 30 September 2018, as reported in these unaudited standalone financial results have been approved by the Board of Directors of the Company but have not been subjected to review.
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



BSR & Co (a partnership firm with
Registration No. BA61223) converted into
BSR & Co. LLP (a Limited Liability, Partnership
with LLP Registration No. AAB-8181)
with effect from October 14, 2013

Registered Office:
5th Floor, Lodha Excelus
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011, India

Limited Review Report on Unaudited Quarterly and Year to Date Standalone Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Wockhardt Limited

5. The comparative financial results of the Company for the quarter and six months ended 30 September 2018 and for the year ended 31 March 2019 included in this Statement had been reviewed/audited by the predecessor auditors who had expressed an unmodified opinion thereon as per their reports dated 10 November 2018 and 6 May 2019 respectively. Additionally, the report of the predecessor auditors dated 14 August 2019 on the financial results for the quarter ended 30 June 2019 which have been included in this Statement, expressed an unmodified opinion and which has been furnished to us by the Management and has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For BSR & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022



Koosai Lehery

Partner

Membership No: 112399

UDIN: 19112399AAAABV4605

Place: Mumbai

Date: 7 November 2019

BSR & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Wockhardt Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), for the quarter ended and year to date results for the period from 1 April 2019 to 30 September 2019 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’). Attention is drawn to the fact that the figures for net cash outflows for the corresponding period from 1 April 2018 to 30 September 2018, as reported in these unaudited consolidated financial results have been approved by the Board of Directors of the Company but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the financial information of the following entities:

Name of the Entity	Relationship
1) Wockhardt UK Holdings Limited (including its following subsidiaries) a) Wallis Group Limited b) The Wallis Laboratory Limited c) Wallis Licensing Limited d) Wockhardt Farmaceutica Do Brasil Ltda	Wholly Owned Subsidiary



BSR & Co (a partnership firm with
Registration No. BA61223) converted into
BSR & Co. LLP (a Limited Liability, Partnership
with LLP Registration No. AAB-8181)
with effect from October 14, 2013

Registered Office:
5th Floor, Lodha Excelus
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011, India

Limited Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Wockhardt Limited

Name of the Entity	Relationship
2) Wockhardt Infrastructure Development Limited	Wholly Owned Subsidiary
3) Wockhardt Europe Limited (including its following wholly owned subsidiary) a) Wockhardt Nigeria Limited	Wholly Owned Subsidiary
4) Wockhardt Medicines Limited	Wholly Owned Subsidiary
5) Wockhardt Bio AG (including its following subsidiaries) a) CP Pharmaceuticals Limited b) CP Pharma (Schweiz) AG c) Z & Z Services GmbH d) Wockhardt USA LLC e) Wockhardt UK Limited f) Wockpharma Ireland Limited g) Pinewood Laboratories Limited h) Pinewood Healthcare Limited i) Laboratories Negma S.A.S. j) Wockhardt France (Holdings) S.A.S. k) Wockhardt Holding Corp. l) Morton Grove Pharmaceuticals Inc. m) MGP Inc. n) Laboratories Pharma 2000 S.A.S. o) Niverpharma S.A.S. p) Negma Beneulex S.A. q) Phytex S.A.S. r) Wockhardt Farmaceutica SA DE CV s) Wockhardt Services SA DE CV t) Wockhardt Bio (R) LLC u) Wockhardt Bio Pty Limited v) Wockhardt Bio Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Limited Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Wockhardt Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Wockhardt Limited

6. We did not review the interim financial information of four subsidiaries included in the Statement, whose interim financial information reflect total assets of Rs 6,364.32 crores as at 30 September 2019 and total revenues of Rs 601.60 crores and Rs 1,287.45 crores, total net loss after tax of Rs 101.13 crores and Rs 63.50 crores and total comprehensive loss of Rs 105.88 crores and Rs 70.74 crores, for the quarter ended 30 September 2019 and for the period from 1 April 2019 to 30 September 2019, respectively, and cash outflows (net) of Rs 107.07 crores for the period from 01 April 2019 to 30 September 2019, as considered in the consolidated unaudited financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

The Statement includes the interim financial information of twenty two subsidiaries which have not been reviewed, whose interim financial information reflect total assets of Rs 191.76 crores as at 30 September 2019 and total revenue of Rs 34.11 crores and Rs 57.39 crores, total net loss after tax of Rs 0.24 crores and Rs 3.31 crores and total comprehensive loss of Rs 0.24 crores and Rs 3.31 crores for the quarter ended 30 September 2019 and for the period from 1 April 2019 to 30 September 2019, respectively, and cash outflows (net) of Rs 6.53 crores for the period from 1 April 2019 to 30 September 2019, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

7. The comparative financial results of the Company for the quarter and six months ended 30 September 2018 and for the year ended 31 March 2019 included in this Statement had been reviewed/audited by the predecessor auditors who had expressed an unmodified opinion thereon as per their reports dated 10 November 2018 and 6 May 2019 respectively. Additionally, the report of the predecessor auditors dated 14 August 2019 on the financial results for the quarter ended 30 June 2019 which have been included in this Statement, expressed an unmodified opinion and which has been furnished to us by the Management and has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Koosai Leheriy
Partner

Place: Mumbai
Date: 7 November 2019

Membership No: 112399
UDIN:19112399AAAABW5062

Mumbai, 7th November, 2019

**Wockhardt H1FY20 sales at Rs. 1,665 crore,
 EBITDA in H1 FY 20 at Rs.99 crore up by 23%**

	Q2-FY20	Q1-FY20	Q2-FY19	H1-FY20	H1-FY19
	Jul - Sep 2019	Apr - Jun 2019	Jul - Sep 2018	Apr - Sep 2019	Apr - Sep 2018
	INR Cr	INR Cr	INR Cr	INR Cr	INR Cr
Sales	802	863	1,125	1,665	2,133
EBITDA before R&D*	103	116	134	219	224
EBITDA % to Sales	12.8%	13.5%	11.9%	13.2%	10.5%
R&D	60	60	82	120	143
R&D % to Sales	7.4%	7.0%	7.3%	7.2%	6.7%
EBITDA *	43	56	52	99	81
EBITDA Margins %	5.4%	6.5%	4.6%	6.0%	3.8%
PBT	(71)	(78)	(32)	(148)	(132)
Profit After Tax	(82)	(45)	(23)	(127)	(109)
PAT Margins %	-10.2%	-5.2%	-2.0%	-7.6%	-5.1%
EPS (Rs)	(7.4)	(4.1)	(2.1)	(11.5)	(9.9)

*Inclusive of impact of IND AS 116 (Lease Accounting) in H1 FY20.

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 2nd Quarter Results for Financial Year 2019-20, today.

Business review for the 2nd quarter and half year ended 30th September, 2019:

The business performance of the Company during the quarter ended 30th September, 2019 remained steady. However, H1FY20 EBITDA showed an improvement from Rs. 81 crore to Rs. 99 crore over previous year.

Sales during Q2 FY20 were at Rs. 802 crore, lower by 29% as compared to corresponding quarter of previous year.

PRESS RELEASE

WOCKHARDT

**LIFE
WINS**

Wockhardt Limited
| D-4, MIDC, Chikalthana |
| Aurangabad |
| Maharashtra | | 431 006 |
| India |
| Tel.: +91-22-2653 4444 |
| www.wockhardt.com

The focus in strategic R&D initiatives of the Company in the global arena continued to remain one of the key priorities. Such strategic R&D expenses though meant for the future are expensed off.

US Business stood at Rs.145 crore in Q2FY20 as compared to Rs.186 crore in Q2FY19. US Business contributed 18% of the Global Revenue.

Emerging Market Business of the Company stood at Rs.132 crore in Q2FY20 (PY Rs.144 crore). Emerging Market business contributed about 16% of the Global Revenue

UK Business during the quarter stood at Rs.223 crore in Q2FY20 (PY Rs.251 crore). UK Business contributed about 28% of Global Revenue.

Irish Business was Rs.39 crore in Q2FY20 (PY Rs.42 crore).

India Business stood at Rs.227 crore in Q2FY20 as compared to Rs.455 crore in Q2FY19. The de-growth is mainly on account of lower sales in Quality Generics division and in some of the therapeutic areas. India Business contributed 28% of the Global Revenue.

Total EU Business contributed 37% of the Global Revenue.

Research & Development expenditure during the quarter was at Rs.60 crore (7% to sales) and including capital expenditure is at 13% to sales.

Capital expenditure during the quarter was Rs.71 crore.

Half year ended 30th September, 2019:

US Business stood at Rs.331 crore in H1FY20 as compared to Rs.369 crore in H1FY19. US Business contributed 20% of the Global Revenue.

Emerging Market Business of the Company recorded a growth of 5% in H1FY20 over H1FY19 and contributed about Rs.276 crore. (about 17% of the Global Revenue)

UK Business stood at Rs.447 crore in H1FY20 as compared to Rs.489 crore in H1FY19. UK Business contributed about 27% of Global Revenue.

Irish Business stood at Rs.77 crore in H1FY20 as compared to Rs.86 crore H1FY19. Irish business contributed to about 5% of the Global Revenue.

India Business stood at Rs.471 crore in H1FY20 as compared to Rs.850 crore in H1FY19. The de-growth is mainly on account of lower sales in Quality Generics division and in some of the therapeutic areas. India Business contributed 28% of the Global Revenue.

Total EU Business contributed 35% of the Global Revenue.

Research & Development expenditure during H1FY20 was at Rs.120 crore (7% to sales) and including capital expenditure is at 13% to sales.

Capital expenditure during H1FY20 was Rs.121 crore.

Debt Repayment :

During the half year ended 30th September, 2019 the Company repaid Rs. 408 crore towards various Long term debt obligations as per schedule. Total Long term outstanding debts as on 30th September, 2019 was Rs. 2,098 crore as compared to Rs. 2,789 crore as on 30th September, 2018 and Rs 2,469 crore as on 31st March, 2019. Gross Debt- Equity ratio as on 30th September 2019 stood at 0.94

Intellectual Property (IP) :

The company's continued pursuit in creating strong **Intellectual Property (IP)** base resulted into filing of 14 patents **during the Quarter ended 30th September, 2019** taking the cumulative filings to 3,157. The company was granted 9 patents during the quarter and now holds 708 patents.

About Wockhardt :

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 5 of our Anti-bacterial discovery programmes – 2 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing over 7000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 72% of its global revenues coming from international businesses.

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
CIN:L24230MH1999PLC120720

Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

**Extract of Unaudited Consolidated Financial Results
For the Quarter and Six Months ended September 30, 2019**

Particulars	Rs. in Crore (except per share data)					
	3 MONTHS ENDED 30/09/2019	3 MONTHS ENDED 30/06/2019	3 MONTHS ENDED 30/09/2018	6 MONTHS ENDED 30/09/2019	6 MONTHS ENDED 30/09/2018	YEAR ENDED 31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from Operations	802.18	863.11	1,125.68	1,665.29	2,133.39	4,158.38
Net Profit / (Loss) (before tax, Exceptional and / or Extraordinary Items)	(70.55)	(77.86)	(31.79)	(148.41)	(131.73)	(300.32)
Net Profit / (Loss) before tax (after Exceptional and / or Extraordinary items)	(70.55)	(77.86)	(31.79)	(148.41)	(131.73)	(300.32)
Net Profit / (Loss) after tax and non-controlling interest (after Exceptional and / or Extraordinary items)	(82.17)	(44.98)	(22.77)	(127.15)	(108.95)	(194.53)
Total Comprehensive Income / (Loss) (Comprising of Profit / (Loss) after tax and Other Comprehensive Income after tax)	(107.41)	(30.73)	75.79	(138.14)	8.89	(207.66)
Paid-up Equity Share Capital (Face value of Rs. 5/- each) Other Equity excluding Revaluation Reserves as shown in the audited Balance Sheet	55.37	55.35	55.33	55.37	55.33	55.34 2,619.46
Earnings per share (Face value of Rs 5/- each) * Not annualised						
Basic Rs.	(7.42)*	(4.06)*	(2.06)*	(11.49)*	(9.85)*	(17.58)
Diluted Rs.	(7.42)*	(4.06)*	(2.06)*	(11.49)*	(9.85)*	(17.58)

Notes:

1. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 07, 2019. The results have been subjected to limited review by the Statutory Auditors of the Company.

2. Information on Standalone Financial Results are as follows:

Particulars	3 MONTHS ENDED 30/09/2019	3 MONTHS ENDED 30/06/2019	3 MONTHS ENDED 30/09/2018	6 MONTHS ENDED 30/09/2019	6 MONTHS ENDED 30/09/2018	YEAR ENDED 31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from Operations	424.28	352.21	634.59	776.49	1,173.95	2,149.95
Profit / (Loss) Before Tax	1.48	(133.18)	8.58	(131.70)	(8.30)	(175.43)
Profit / (Loss) After Tax	0.07	(82.93)	5.10	(82.86)	(10.01)	(81.89)

3. The above is an extract of the detailed format of the Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results are available on the websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com) and on the Company's website (www.wockhardt.com).

Mumbai
Date : November 07, 2019



For WOCKHARDT LIMITED

H F KHORAKIWALA
CHAIRMAN
DIN : 00045608